{
    "clinical_study": {
        "@rank": "137898", 
        "acronym": "CHARTRES", 
        "arm_group": {
            "arm_group_label": "Patients with DME", 
            "description": "Patients with DME who need treatment with anti-VEGF injections of Lucentis."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to identify Diabetic Macular Edema (DME) characteristics in\n      eyes that show different response to treatment with anti-VEGF (vascular endothelial growth\n      factor) injections of Lucentis."
        }, 
        "brief_title": "Characterization of Eyes With Diabetic Macular Edema That Show Different Treatment Response to Intravitreal Anti-VEGF (CHARTRES)", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Macular Edema", 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with 40 years of age or older.\n\n          -  Type 2 Diabetes Mellitus.\n\n          -  Glycosylated hemoglobin (HbA1C) \u2264 12% at screening visit.\n\n          -  Presence of clinically significant DME involving the center (fovea) diagnosed in at\n             least one eye that is eligible for anti-VEGF treatment in the opinion of the\n             investigator. If both eyes are eligible, the one with the worse visual acuity, as\n             assessed at screening visit, will be selected as the study eye.\n\n          -  Visual impairment due to DME with BCVA \u2265 39 letters and \u2264 73 letters (\u2265 20/160 and \u2264\n             20/40).\n\n          -  Central subfield thickness \u2265 300\u00b5m.\n\n        Exclusion Criteria:\n\n          -  Presence of any other ocular disease than DME in the study eye that may confound\n             study results, such as Proliferative Retinopathy.\n\n          -  Previous treatment with vitrectomy or intravitreous injections of triancinolone or\n             anti-VEGF drugs in the study eye.\n\n          -  Any previous laser photocoagulation (panretinal or focal) in the study eye within 6\n             months prior to inclusion in this study.\n\n          -  Active intraocular inflammation (grade trace or above) in either eye at screening\n             visit.\n\n          -  Any active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis,\n             endophthalmitis) in either eye at screening visit.\n\n          -  Important refractive errors (myopia > 6D) or opacification of clear media that\n             interferes with images evaluation.\n\n          -  Patients with renal failure or other systemic conditions which, in the opinion of the\n             investigator, would preclude schedule study visits, completion of the study or a safe\n             administration of study medication.\n\n          -  Other criteria that in the opinion of the investigator should condition the\n             evaluation purposed."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Diabetic Type 2 patients with clinically significant Diabetic Macular Edema with\n        therapeutic indication for treatment with intravitreal injections of anti-VEGF Lucentis."
            }
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01947881", 
            "org_study_id": "4C-2013-05"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diabetic Macular Edema", 
            "anti-VEGF", 
            "Treatment Response"
        ], 
        "lastchanged_date": "April 9, 2014", 
        "location": {
            "contact": {
                "email": "4c@aibili.pt", 
                "last_name": "Jo\u00e3o Figueira, MD", 
                "phone": "+351 239 480 100"
            }, 
            "facility": {
                "address": {
                    "city": "Coimbra", 
                    "country": "Portugal", 
                    "zip": "3000-548"
                }, 
                "name": "Centre for Clinical Trials - Association for Innovation and Biomedical Research on Light and Image"
            }, 
            "investigator": {
                "last_name": "Jo\u00e3o Figueira, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Portugal"
        }, 
        "number_of_groups": "1", 
        "official_title": "Characterization of Eyes With Diabetic Macular Edema That Show Different Treatment Response to Intravitreal Anti-VEGF (CHARTRES)", 
        "overall_contact": {
            "email": "4c@aibili.pt", 
            "last_name": "Jos\u00e9 Cunha-Vaz, MD, PhD", 
            "phone": "00351 239 480 142"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Portugal: Ethics Committee for Clinical Research", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Measured by Spectral Domain Optical Coherence Tomography (OCT)", 
                "measure": "Central Retinal Thickness (Change from screening)", 
                "safety_issue": "No", 
                "time_frame": "Change from Screening at 3 Months"
            }, 
            {
                "measure": "Presence (and location) of cysts in the retinal layers (change from screening)", 
                "safety_issue": "No", 
                "time_frame": "Change from Screening at 3 Months"
            }, 
            {
                "measure": "Presence of OCT diffuse macular edema (without cyst formation) (change from screening)", 
                "safety_issue": "No", 
                "time_frame": "Change from Screening at 3 Months"
            }, 
            {
                "measure": "Presence of neurosensorial retinal detachment. (change from screening)", 
                "safety_issue": "No", 
                "time_frame": "Change from Screening at 3 Months"
            }, 
            {
                "measure": "Degree of integrity of the photoreceptors in the inner/outer segments layer in the 1 mm centered in the fovea (change from screening)", 
                "safety_issue": "No", 
                "time_frame": "Change from Screening at 3 Months"
            }, 
            {
                "measure": "Presence and extension of capillary occlusion (change from screening)", 
                "safety_issue": "No", 
                "time_frame": "Change from Screening at 3 Months"
            }, 
            {
                "measure": "Area of macular leakage (intraretinal fluid volume and retinal thickness) (change frmo screening)", 
                "safety_issue": "No", 
                "time_frame": "Change from Screening at 3 Months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01947881"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Best Corrected Visual Acuity (BCVA) (Change from screening)", 
                "safety_issue": "No", 
                "time_frame": "Change from Screening at 3 Months"
            }, 
            {
                "description": "Measured by Spectral Domain Optical Coherence Tomography (OCT)", 
                "measure": "Central Retinal Thickness (change from screening)", 
                "safety_issue": "No", 
                "time_frame": "Change from Screening at 6 Months"
            }, 
            {
                "measure": "Presence (and location) of cysts in the retinal layers (change from screening)", 
                "safety_issue": "No", 
                "time_frame": "Change from Screening at 6 Months"
            }, 
            {
                "measure": "Presence of OCT diffuse macular edema (without cyst formation) (change from screening)", 
                "safety_issue": "No", 
                "time_frame": "Change from Screening at 6 months"
            }, 
            {
                "measure": "Presence of neurosensorial retinal detachment.  (change from screening)", 
                "safety_issue": "No", 
                "time_frame": "Change from Screening at 6 Months"
            }, 
            {
                "measure": "Degree of integrity of the photoreceptors in the inner/outer segments layer in the 1 mm centered in the fovea (change from screening)", 
                "safety_issue": "No", 
                "time_frame": "Change from Screening at 6 months"
            }, 
            {
                "measure": "Presence and extension of capillary occlusion  (change from screening)", 
                "safety_issue": "No", 
                "time_frame": "Change from Screening at 6 Months"
            }, 
            {
                "measure": "Area of macular leakage (intraretinal fluid volume and retinal thickness) (change from screening)", 
                "safety_issue": "No", 
                "time_frame": "Change from Screening at 6 Months"
            }, 
            {
                "measure": "Best Corrected Visual Acuity (change from screening)", 
                "safety_issue": "No", 
                "time_frame": "Change from Screening at 6 Months"
            }
        ], 
        "source": "Association for Innovation and Biomedical Research on Light and Image", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Association for Innovation and Biomedical Research on Light and Image", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}